Licensing status

Publication and contact information

Drug platforms

Boosting antitumor immune response by blocking glycolysis

A study in mice suggests blocking glycolysis with a small molecule could help enhance an antitumor immune response. In a mouse tumor model, a combination of the chemotherapeutic agent etoposide with a low dose of the glycolysis inhibitor 2-deoxy-d-glucose (2-DG) increased an antitumor T cell response and survival and decreased tumor size compared with either treatment alone. Next steps include testing 2-DG in combination with other chemotherapeutics.

In 2011, Threshold Pharmaceuticals Inc. discontinued development of 2-DG, which was in Phase I testing for solid tumors.

SciBX 5(48); doi:10.1038/scibx.2012.1270
Published online Dec. 13, 2012

Patent pending; available for licensing

Bénéteau, M. et al. Proc. Natl. Acad. Sci. USA; published online Nov. 19, 2012;
Contact: Jean-Ehrland Ricci, Institut National de la Santé et de la Recherche Médicale (INSERM), Nice, France